Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment.
A radioimmunoassay procedure was used to determine levels of somatostatin-like immunoreactivity in cerebrospinal fluid obtained from 9 schizophrenic patients, 7 patients with other psychiatric disorders, and 10 nonpsychiatric surgical controls. There were no significant differences in mean somatostatin baseline levels between the schizophrenic, nonschizophrenic, and surgical patients. The concentration remained almost unaltered after 4 weeks of zuclopenthixol treatment in the schizophrenia group and following various neuroleptic, antidepressant, and anxiolytic medications in the nonschizophrenic patients despite a significant decrease of overt psychopathology assessed by the Brief Psychiatric Rating Scale.
Heikkilä
L
L
Uusikaupunki Hospital, Finland.
D000328:Adult; D001883:Borderline Personality Disorder / Q000134:cerebrospinal fluid / Q000188:drug therapy; D002908:Chronic Disease; D003006:Clopenthixol / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000134:cerebrospinal fluid / Q000188:drug therapy; D011569:Psychiatric Status Rating Scales; D011619:Psychotropic Drugs / Q000627:therapeutic use; D011863:Radioimmunoassay; D012559:Schizophrenia / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013004:Somatostatin / Q000134:cerebrospinal fluid*
D011619:Psychotropic Drugs; D013004:Somatostatin; D003006:Clopenthixol; D008140:Lorazepam